



FEATURED OPTIONS RADAR REPORT




Healthcare Leader Sees Put Seller into Recent Pullback

Ticker/Price: ABBV (\$149.50)

Analysis:

Abbvie (ABBV) on 7/26 with a large opening put seller in January \$130 puts sold 4000 times for \$3.95, over \$1.58M in premium collected calling a floor near the recent June lows. ABBV has also seen put sales in February \$110 puts, August \$130 puts, and sizeable amounts sold in November \$115 puts 5000x at \$2.19 and 1400x in June \$130 puts at \$9.75. Willing bulls ready to be long shares at those levels. Shares have consolidated nicely the past month near the YTD VWAP at 150 after seeing a strong advance off the June lows which found support at the 200 EMA close to 135. ABBV is one of the few names that has been positive year to date all through 2022 and hit a high of 175 before the broad market selloff. A solid weekly chart trying to base near the 21-week EMA and resume its long-term uptrend. On a move higher first resistance is at 157.50 and then has lots of space to breakout above. The \$266.6B company trades 11.8x earnings, 5.8x EV/sales, with a FCF yield of 8.6% and a 3.8% dividend yield. The company reports earnings on 7/29 and has been higher in 5 of the last 8 reports with a median closing move of +0.87%. Consensus looking for \$3.30 EPS and \$14.63B in Revenue. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics. On the last earnings call ABBV mentioned some of its exciting growth areas including Skyrizi performing exceptionally well. We are achieving impressive market share gains in psoriasis, which remains a significant market opportunity. Skyrizi's recent launch in psoriatic arthritis as well as the anticipated regulatory approval in Crohn's disease should also serve as important growth drivers over the long term. Average analyst target is \$160 with a Street high of \$200. In early July, Morgan Stanley boosted its target to \$191 and kept an Overweight rating and in May, Wells Fargo a big bull on the name raising their price target to \$200. Short interest is at 1.0%. Hedge fund ownership fell 3.4%.

Hawk Vision:



Hawk's Perspective: ABBV is coiling nicely into earnings and a move above 153 can likely breakout. If comfortable with short puts, then selling the January's is not a bad idea.

Confidence Ranking: \$\$